Can fibrinolytic therapy be clinically useful in severe pneumonia caused by COVID-19?
J Thromb Thrombolysis
.
2021 Apr;51(3):633-636.
doi: 10.1007/s11239-020-02247-9.
Epub 2020 Aug 12.
Authors
Rafael Bornstein
1
,
José Antonio Páramo
2
Affiliations
1
Servicio de Hematología y Hemoterapia, Hospital Central de Cruz Roja, Madrid, Spain. rbornstein@salud.madrid.org.
2
Departamento de Hematología y Hemoterapia, Clínica Universidad de Navarra, Pamplona, Spain.
PMID:
32785830
DOI:
10.1007/s11239-020-02247-9
No abstract available
Publication types
Review
MeSH terms
COVID-19 Drug Treatment*
Fibrinolytic Agents / therapeutic use*
Humans
Substances
Fibrinolytic Agents